Effects of PPARγ and RBP4 gene variants on metabolic syndrome in HIV-infected patients with anti-retroviral therapy

• Published in: PloS one Vol. 7; no. 11; p. e49102
• Main Authors: Hung, Yuan-Pin, Lee, Nan-Yao, Lin, Sheng-Hsiang, Chang, Ho-Ching, Wu, Chi-Jung, Chang, Chia-Ming, Chen, Po-Lin, Lin, Hsiao-Ju, Wu, Yi-Hui, Tsai, Pei-Jane, Tsai, Yau-Sheng, Ko, Wen-Chien
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 07.11.2012; Public Library of Science (PLoS)
• Subjects: Acquired immune deficiency syndrome; Adult; Adults; AIDS; Alleles; Antiretroviral agents; Antiretroviral drugs; Antiretroviral therapy; Antiretroviral Therapy, Highly Active; Biology; Cross-Sectional Studies; Drugs; Female; Genetic Predisposition to Disease; Genotype; Glucose metabolism; Health risks; HIV; HIV Infections - complications; HIV Infections - drug therapy; HIV Infections - genetics; HIV Infections - metabolism; HIV-1 - genetics; Human immunodeficiency virus; Humans; Hypercholesterolemia; Hypertriglyceridemia; Insulin; Insulin resistance; Insulin Resistance - genetics; Lipid metabolism; Low density lipoprotein; Male; Males; Medicine; Metabolic syndrome; Metabolic Syndrome - complications; Metabolic Syndrome - drug therapy; Metabolic Syndrome - metabolism; Metabolism; Middle Aged; Multivariate analysis; Mutation; Patients; Polymorphism; Polymorphism, Single Nucleotide; PPAR gamma - genetics; Retinol-Binding Proteins, Plasma - genetics; Therapy; Trends; Young Adult; Taiwan
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0049102

PPARγ and RBP4 are known to regulate lipid and glucose metabolism and insulin resistance. The influences of PPARγ (C1431T and Pro12Ala) and RBP4 (-803GA) polymorphisms on metabolic syndrome in HIV-infected patients receiving anti-retroviral therapy were examined in this study. A cross-sectional study of HIV-1 infected adults with antiretroviral therapy for more than one year in the National Cheng Kung University Hospital was conducted. The gene polymorphisms were determined by quantitative PCR. Ninety-one patients were included in the study. Eighty-two (90.1%) patients were males with a mean age of 44.4 years. For the C1431T polymorphism in PPARγ, while patients with the T allele (48.4%) had trends toward lower rate of hypertriglyceridemia, the borderline significance together with insignificant power did not support the protective effect of the T allele against development of hypertriglyceridemia. For the Pro12Ala polymorphism in PPARγ, although patients with the Pro/Ala genotype (8.8%) had a higher level of serum LDL (138.0 vs. 111.5 mg/dl, P = 0.04) and trends toward higher rates of hypercholesterolemia and serum LDL>110 mg/dl, these variables were found to be independent of the Pro/Ala genotype in the multivariate analysis. For the -803GA polymorphism in RBP4, patients with the A allele (23.1%) more often had insulin resistance (HOMA>3.8; 33.3 vs. 8.7%, P = 0.01) and more often received anti-hypoglycemic drugs (14.3 vs. 1.4%, P = 0.04). The detrimental effect of the A allele in RBP4 -803GA polymorphism on development of insulin resistance was supported by the multivariate analysis adjusting for covariates. The impacts of PPARγ C1431T and Pro12Ala polymorphisms on metabolism in HIV-infected patients are not significant. RBP4 -803GA polymorphism has increased risk of insulin resistance in HIV-infected patients with anti-retroviral therapy.